Vivaar Exim Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 10-12-2024
- Paid Up Capital ₹ 0.10 M
as on 10-12-2024
- Company Age 12 Year, 12 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 14.30 Cr
as on 10-12-2024
- Satisfied Charges ₹ 5.00 M
as on 10-12-2024
- Revenue %
(FY 2022)
- Profit 1540.00%
(FY 2022)
- Ebitda -163.33%
(FY 2022)
- Net Worth 406.80%
(FY 2022)
- Total Assets 2.45%
(FY 2022)
About Vivaar Exim
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹14.30 Cr. The company has closed loans amounting to ₹5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Meera Pruthi and Rajeev Kumar serve as directors at the Company.
- CIN/LLPIN
U24233DL2013PTC247115
- Company No.
247115
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jan 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Vivaar Exim?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meera Pruthi  | Director | 23-Aug-2021 | Current |
| Rajeev Kumar | Director | 23-Aug-2021 | Current |
Financial Performance of Vivaar Exim.
Vivaar Exim Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 1540% increase in profit. The company's net worth Soared by an impressive increase of 406.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vivaar Exim?
Unlock access to Vivaar Exim's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Aaloha Lifesciences Private LimitedActive 12 years 2 monthsMeera Pruthi and Rajeev Kumar are mutual person
- Vinman Health Private LimitedActive 12 years 4 months
Meera Pruthi and Rajeev Kumar are mutual person
- Girisha Lifesciences Private LimitedActive 6 years 4 months
Meera Pruthi and Rajeev Kumar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 18 Sep 2013 | ₹14.30 Cr | Open |
Canara Bank Creation Date: 16 Dec 2015 | ₹5.00 M | Satisfied |
How Many Employees Work at Vivaar Exim?
Unlock and access historical data on people associated with Vivaar Exim, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vivaar Exim, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vivaar Exim's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
